| Literature DB >> 31319988 |
Christoph Jakob Ackermann1, Martin Reck2, Luis Paz-Ares3, Fabrice Barlesi4, Raffaele Califano5.
Abstract
The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential of immunotherapy (IO) to induce durable responses for a subset of patients represents a therapeutic milestone. After the approval of front-line single agent pembrolizumab, IO-based combinations are rapidly entering clinical practice resulting in a fast change of treatment algorithms for advanced NSCLC. We hereby summarize the recent first-line phase 3 trials evaluating PD-(L)1 blockade plus chemotherapy (ChT) and PD-1 plus CTLA-4 CPI for advanced NSCLC and provide potential treatment recommendations. CrownEntities:
Keywords: Advanced; CTLA-4; Checkpoint inhibitors; Chemotherapy; First-line; Immuno-Oncology; Immunotherapy; NSCLC; Non-Small-Cell Lung Cancer; PD-1; PD-L1
Mesh：
Substances：
Year: 2019 PMID： 31319988 DOI： 10.1016/j.lungcan.2019.06.007
Source DB: PubMed Journal: Lung Cancer ISSN： 0169-5002 Impact factor: 5.705